Samsung is looking to launch its flagship Galaxy S21 smartphones a month earlier than planned next year to grab Huawei's market share and fend off competition from Apple Inc.
The new Galaxy S21 may come out as early as late January next year, rather than in March when Samsung previously launched its flagship S20 phone this year.
Samsung shipped 59 percent less Galaxy S20 5G series handsets in the US in the second quarter than its previous flagship model in the same period last year.
In contrast, Apple's shipment of its flagship iPhone 11 increased by 15 percent than its iPhone XR in 2019.
Samsung lost its No.1 position to Huawei in the second quarter but regained it in the third due in part to the US restrictions on the Chinese smartphone maker.
According to an industry insider, Huawei’s stockpiles smartphone chips may run out by early next year.
However, other Chinese brands such as Xiaomi and Oppo are vying for Huawei’s previous market share.
The launch of Apple's iPhone series is in October, about a month later than usual.


Alibaba Sells Lingxi Games for Over $1.5 Billion Amid AI Push
Moody’s Upgrades Vodafone Hybrid Debt Ratings to Baa3
Hermès Stock Downgraded by RBC as Luxury Growth Premium Narrows
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised
Sun Pharma Wins U.S. Appeal in Pfizer Lipitor Antitrust Case
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
Google to Move All Pixel Production Out of China by 2027
Coty Revenue Beats Estimates as Beauty Demand Holds Firm
Google to Buy Spirit Airlines Business Data for $10 Million to Train AI
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits
Lockheed Martin Secures $153.5 Million in U.S. Defense Contracts
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion
Schott Pharma Stock Rises as Barclays Upgrades Rating on Growth Outlook
OpenAI Tightens AI Safety Monitoring After Security Incidents 



